Loading...
Strategies, Design, and Chemistry in siRNA Delivery Systems
Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad classes of diseases due to their ability to reversibly silence target genes. In August 2018, the FDA approved the first siRNA therapeutic, called ONPATTRO™ (Patisiran), for the treatment of transthyretin-med...
Na minha lista:
| Udgivet i: | Adv Drug Deliv Rev |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6745264/ https://ncbi.nlm.nih.gov/pubmed/31102606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.addr.2019.05.004 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|